Erratum: Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms (British Journal of Pharmacology (2006) 148, (102-113) doi:10.1038/sj.bjp.0706699);Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms

British Journal of Pharmacology

Volumn 148, Issue 1, 2006, Pages 102-113

  Chang, Leon ^a   Luo, Lin ^a   Palmer, James A ^a   Sutton, Steven ^a   Wilson, Sandy J ^a   Barbier, Ann J ^a   Breitenbucher, James Guy ^a   Chaplan, Sandra R ^a   Webb, Michael ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Analgesia; Cannabinoid receptor; Endocannabinoid; FAAH; Fatty acid amide; Fatty acid amide hydrolase; Naloxone; Pain

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENZYME INHIBITOR; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; NALOXONE; OL 135; OPIATE RECEPTOR; RIMONABANT; UNCLASSIFIED DRUG; URL 597;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG MECHANISM; MALE; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL NERVE; THERMAL INJURY;

EID: 33646431125     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706773     Document Type: Erratum

References (64)

1. AHLUWALIA, J., URBAN, L., BEVAN, S. & NAGY, I. (2003). Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur. J. Neurosci., 17, 2611-2618.
2. AHLUWALIA, J., URBAN, L., CAPOGNA, M., BEVAN, S. & NAGY, I. (2000). Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience, 100, 685-688.
3. BARANN, M., MOLDERINGS, G., BRUSS, M., BONISCH, H., URBAN, B.W. & GOTHERT, M. (2002). Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br. J. Pharmacol., 137, 589-596.
4. BISOGNO, T., DE PETROCELLIS, L. & DI MARZO, V. (2002). Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr. Pharm. Des., 8, 533-547.
5. CADAS, H., GAILLET, S., BELTRAMO, M., VENANCE, L. & PIOMELLI, D. (1996). Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci., 16, 3934-3942.
6. CALIGNANO, A., LA RANA, G., GIUFFRIDA, A. & PIOMELLI, D. (1998). Control of pain initiation by endogenous cannabinoids. Nature, 394, 277-281.
7. CALIGNANO, A., LA RANA, G. & PIOMELLI, D. (2001). Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur. J. Pharmacol., 419, 191-198.
8. CALIXTO, J.B., BEIRITH, A., FERREIRA, J., SANTOS, A.R., FILHO, V.C. & YUNES, R.A. (2000). Naturally occurring antinociceptive substances from plants. Phytother. Res. Sep., 14, 401-418.
9. CARLINI, E.A. (2004). The good and the bad effects of (-) trans-delta-9-tetrahydrocannbinol (Delta 9 THC) on humans. Toxicon, 44, 461-467.
10. CHAPLAN, S.R., BACH, F.W., POGREL JW SNL, J.M. & YAKSH, T.L. (1994). Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods, 53, 55-63.
11. CRAVATT, B.F., DEMAREST, K., PATRICELLI, M.P., BRACEY, M.H., GIANG, D.K., MARTIN, B.R. & LICHTMAN, A.M. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U.S.A., 98, 9371-9376.
12. DEVANE, W.A., HANUS, L., BREUER, A., PERTWEE, R.G., STEVENSON, L.A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
13. DI MARZO, V., DE PETROCELLIS, L., FEZZA, F., LIGRESTI, A. & BISOGNO, T. (2002). Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids, 66, 377-391.
14. DI MARZO, V., FONTANA, A., CADAS, H., SCHINELLI, S., CIMINO, G., SCHWARTZ, J.C. & PIOMELLI, D. 1994. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 372, 686-691.
15. 35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur. J. Neurosci., 12, 2079-2086.
16. EDSALL, S.A., KNAPP, R.J., VANDERAH, T.W., ROESKE, W.R., CONSROE, P. & YAMAMURA, H.I. (1996). Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. NeuroReport, 7, 593-596.
17. ELPHICK, M. & EGERTOVA, M. (2001). The neurobiology and evolution of cannabinoid signaling. Phil. Trans. R. Soc. London B, 356, 381-408.
18. FAN, P. (1995). Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J. Neurophysiol., 73, 907-910.
19. FEGLEY, D., GAETANI, S., DURANTI, A., TONTINI, A., MOR, M., TARZIA, G. & PIOMELLI, D. (2005). Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther., 313, 352-358.
20. FRANKLIN, A. & STELLA, N. (2003). Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors. Eur. J. Pharmacol., 474, 195-198.
21. GARDNER, E.L. (2005). Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol. Biochem. Behav., 81, 263-284.
22. GEBREMEDHIN, D., LANGE, A.R., CAMPBELL, W.B., HILLARD, C.J. & HARDER, D.R. (1999). Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am. J. Physiol., 276, 2085-2093.
23. GIANG, D.K. & CRAVATT, B.F. (1997). Molecular characterization of human and mouse fatty acid amide hydrolases. Proc. Natl. Acad. Sci. U.S.A., 94, 2238-2242.
24. GOURLAY, D. (2005). Addiction and pain medicine. Pain Res. Manag., 10 (Suppl A), 38A-43A.
25. GUO, J. & IKEDA, S.R. (2004). Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. Mol. Pharmacol., 65, 665-674.
26. HAMPSON, A.J., BORNHEIM, L.M., SCANZIANI, M., YOST, C.S., GRAY, A.T., HANSEN, B.M., LEONOUDAKIS, D.J. & BICKLER, P.E. (1998). Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J. Neurochem., 70, 671-676.
27. HOHMANN, A.G., FARTHING, J.N., ZVONOK, A.M. & MAKRIYANNIS, A. (2004). Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J. Pharmacol. Exp. Ther., 308, 446-453.
28. HOLT, S., COMELLI, F., COSTA, B. & FOWLER, C. (2005). Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br. J. Pharmacol., 146, 467-476.
29. HUA, X.Y., SVENSSON, C., MATSUI, T., FITZSIMMONS, B., YAKSH, T.L. & WEBB, M. (2005). Intrathecal minocycline attenuates peripheral inflammation-induced hyperalgesia by inhibiting p38 MAPK in spinal microglia. Eur. J. Neurosci., 22, 2431-2440.
30. IBRAHIM, M.M., DENG, H., ZVONOK, A., COCKAYNE, D.A., KWAN, J., MATA, H.P., VANDERAH, T.W., LAI, J., PORRECA, F., MAKRIYANNIS, A. & MALAN Jr, T.P. (2003). Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl. Acad. Sci. U.S.A., 100, 10529-10533.
31. IBRAHIM, M.M., PORRECA, F., LAI, J., ALBRECHT, P.J., RICE, F.L., KHODOROVA, A., DAVAR, G., MAKRIYANNIS, A., VANDERAH, T.W., MATA, H.P. & MALAN Jr, T.P. (2005). CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl. Acad. Sci. U.S.A., 102, 3093-3098.
32. JAGGAR, S.I., HASNIE, F.S., SELLATURAY, S. & RICE, A.S. (1998). The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain, 76, 189-199.
33. KELLY, S. & CHAPMAN, V. (2001). Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. J. Neurophysiol, 86, 3061-3064.
34. KIM, S.H. & CHUNG, J.M. (1992). An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain, 50, 355-363.
35. LAMBERT, D.M., VANDEVOORDE, S., JONSSON, K.O. & FOWLER, C.J. (2002). The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr. Med. Chem., 9, 663-674.
36. LEE, E.J., SIM, J.Y., PARK, J.Y., HWANG, J.H., PARK, P.H. & HAN, S.M. (2002). Intrathecal carbachol and clonidine produce a synergistic antiallodynic effect in rats with a nerve ligation injury. Can. J. Anaesth., 49, 178-184.
37. LEUNG, D., DU, W., HARDOUIN, C., CHENG, H., HWANG, I., CRAVATT, B.F. & BOGER, D.L. (2005). Discovery of an exceptionally potent and selective class of fatty acid amide hydrolase inhibitors enlisting proteome-wide selectivity screening: concurrent optimization of enzyme inhibitor potency and selectivity. Bioorg. Med. Chem. Lett., 15, 1423-1428.
38. LICHTMAN, A.H., LEUNG, D., SHELTON, C.C., SAGHATELIAN, A., HARDOUIN, C., BOGER, D.L. & CRAVATT, B.F. (2004a). Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J. Pharmacol. Exp. Ther., 311, 441-448.
39. LICHTMAN, A.H., SHELTON, C.C., ADVANI, T. & CRAVATT, B.F. (2004b). Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain, 109, 319-327.
40. LU, Q., STRAIKER, A., LU, Q. & MAGUIRE, G. (2000). Expression of CB2 cannabinoid receptor mRNA in adult rat retina. Vis. Neurosci., 17, 91-95.
41. MACKIE, K., DEVANE, W.A. & HILLE, B. (1993). Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol., 44, 498-503.
42. MALAN Jr, T.P., IBRAHIM, M.M., DENG, H., LIU, Q., MATA, H.P., VANDERAH, T., PORRECA, F. & MAKRIYANNIS, A. (2001). CB2 cannabinoid receptor-mediated peripheral antinociception. Pain, 93, 239-245.
43. MALAN Jr, T.P., IBRAHIM, M.M., VANDERAH, T.W., MAKRIYANNIS, A. & PORRECA, F. (2002). Inhibition of pain responses by activation of CB(2) cannabinoid receptors. Chem Phys. Lipids, 121, 191-200.
44. MARTIN, W.J., LOO, C.M. & BASBAUM. (1999). AI spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain, 82, 199-205.
45. MATSUDA, L.A., LOLAIT, S.J., BROWNSTEIN, M.J., YOUNG, A.C. & BONNER, T.I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561-564.
46. MONHEMIUS, R., AZAMI, J., GREEN, D.L. & ROBERTS, M.H. (2001). CB1 receptor mediated analgesia from the nucleus reticularis gigantocellularis pars alpha is activated in an animal model of neuropathic pain. Brain Res., 908, 67-74.
47. MOR, M., RIVARA, S., LODOLA, A., PLAZZI, P.V., TARZIA, G., DURANTI, A., TONTINI, A., PIERSANTI, G., KATHURIA, S. & PIOMELLI, D. (2004). Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships and molecular modeling studies. J. Med. Chem., 47, 4998-5008.
48. MUNRO, S., THOMAS, K.L. & ABU-SHAAR, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61-65.
49. NOZAKI-TAGUCHI, N. & YAKSH, T.L. (1998). A novel model of primary and secondary hyperalgesia after mild thermal injury in the rat. Neurosci. Lett., 254, 25-28.
50. NUNEZ, E., BENITO, C., PAZOS, M.R., BARBACHANO, A., FAJARDO, O., GONZALEZ, S., TOLON, R.M. & ROMERO, J.C. (2004). CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse, 53, 208-213.
51. OSSIPOV, M.H., BIAN, D., MALAN Jr, T.P., LAI, J. & PORRECA, F. (1999). Lack of involvement of capsaicin-sensitive primary afferents in nerve-ligation injury induced tactile allodynia in rats. Pain, 79, 127-133.
52. PUIG, S. & SORKIN, L. (1996). Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activity. Pain, 64, 345-355.
53. RICHARDSON, J.D., KILO, S. & HARGREAVES, K.M. (1998). Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain, 75, 111-119.
54. ROBERTS, L.A., CHRISTIE, M.J. & CONNOR, M. (2002). Anandamide is a partial agonist at native vanilloid receptors in acutely isolated mouse trigeminal sensory neurons. Br. J. Pharmacol., 137, 421-428.
55. SCOTT, D.A., WRIGHT, C.E. & ANGUS, J.A. (2004). Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain, 109, 124-131.
56. SUGIURA, T., KONDO, S., SUKAGAWA, A., TONEGAWA, T., NAKANE, S., YAMASHITA, A. & WAKU, K. (1996). Enzymatic synthesis of anandamide, an endogenous cannabinoid receptor ligand, through N-acylphosphatidylethanolamine pathway in testis: involvement of Ca(2+)-dependent transacylase and phosphodiesterase activities. Biochem. Biophys. Res. Commun., 218, 113-117.
57. TSOU, K., BROWN, S., SANUDO-PENA, M.C., MACKIE, K. & WALKER, J.M. (1998). Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience, 83, 393-411.
58. TSUDA, M., INOUE, K. & SALTER, M.W. (2005). Neuropathic pain and spinal microglia: a big problem from molecules in 'small' glia. Trends Neurosci., 28, 101-107.
59. TWITCHELL, W., BROWN, S. & MACKIE, K.J. (1997). Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol., 78, 43-50.
60. VERME, J.L., FU, J., ASTARITA, G., LA RANA, G., RUSSO, R., CALIGNANO, A. & PIOMELLI, D. (2005). The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol., 67, 15-19.
61. WIFFEN, P.J., MCQUAY, H.J., EDWARDS, J.E. & MOORE, R.A. (2005). Gabapentin for acute and chronic pain. Cochrane Database Syst. Rev., 20, CD005452 Review.
62. WILLOUGHBY, K.A., MOORE, S.F., MARTIN, B.R. & ELLIS, E.F. (1997). The biodisposition and metabolism of anandamide in mice. J. Pharmacol. Exp. Ther., 282, 243-247.
63. WILSON, S.J., LOVENBERG, T.W. & BARBIER, A.J. (2003). A high-throughput-compatible assay for determining the activity of fatty acid amide hydrolase. Anal. Biochem., 318, 270-275.
64. ZHANG, J., HOFFERT, C., VU, H.K., GROBLEWSKI, T., AHMAD, S. & O'DONNELL, D. (2003). Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur. J. Neurosci., 17, 2750-2754.